Show simple item record

dc.rights.licenseopenen_US
dc.contributor.authorKRUSE, Christopher
dc.contributor.authorLIPINSKI, Anna
dc.contributor.authorVERHEYEN, Malte
dc.contributor.authorBALZER-GELDSETZER, Monika
dc.contributor.authorWITTENBERG, Michael
dc.contributor.authorLORENZL, Stefan
dc.contributor.authorRICHINGER, Carmen
dc.contributor.authorSCHMOTZ, Christian
dc.contributor.authorTONGES, Lars
dc.contributor.authorWOITALLA, Dirk
dc.contributor.authorKLEBE, Stephan
dc.contributor.authorBLOEM, Bastiaan R
dc.contributor.authorHOMMEL, Adrianus
hal.structure.identifierInstitut des Maladies Neurodégénératives [Bordeaux] [IMN]
dc.contributor.authorMEISSNER, Wassilios G
hal.structure.identifierInstitut des Maladies Neurodégénératives [Bordeaux] [IMN]
dc.contributor.authorLAURENS, Brice
dc.contributor.authorBORAUD, Thomas
hal.structure.identifierInstitut des Maladies Neurodégénératives [Bordeaux] [IMN]
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorSAMIER FOUBERT, Alexandra
hal.structure.identifierInstitut des Maladies Neurodégénératives [Bordeaux] [IMN]
dc.contributor.authorVERGNET, Sylvain
hal.structure.identifierInstitut des Maladies Neurodégénératives [Bordeaux] [IMN]
dc.contributor.authorTISON, Francois
dc.contributor.authorCOSTA, Nadege
dc.contributor.authorODIN, Per
dc.contributor.authorROSQVIST, Kristina
dc.contributor.authorNORLIN, Jenny M
dc.contributor.authorHJALTE, Frida
dc.contributor.authorSCHRAG, Anette
dc.contributor.authorDODEL, Richard
dc.date.accessioned2024-03-12T13:22:27Z
dc.date.available2024-03-12T13:22:27Z
dc.date.issued2024-02-29
dc.identifier.issn1531-8257 (Electronic) 0885-3185 (Linking)en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/188719
dc.description.abstractEnBACKGROUND: Parkinson's disease (PD) is a neurodegenerative disease that leads to progressive disability. Cost studies have mainly explored the early stages of the disease, whereas late-stage patients are underrepresented. OBJECTIVE: The aim is to evaluate the resource utilization and costs of PD management in people with late-stage disease. METHODS: The Care of Late-Stage Parkinsonism (CLaSP) study collected economic data from patients with late-stage PD and their caregivers in five European countries (France, Germany, the Netherlands, UK, Sweden) in a range of different settings. Patients were eligible to be included if they were in Hoehn and Yahr stage >3 in the on state or Schwab and England stage at 50% or less. In total, 592 patients met the inclusion criteria and provided information on their resource utilization. Costs were calculated from a societal perspective for a 3-month period. A least absolute shrinkage and selection operator approach was utilized to identify the most influential independent variables for explaining and predicting costs. RESULTS: During the 3-month period, the costs were €20,573 (France), €19,959 (Germany), €18,319 (the Netherlands), €25,649 (Sweden), and €12,156 (UK). The main contributors across sites were formal care, hospitalization, and informal care. Gender, age, duration of the disease, Unified Parkinson's Disease Rating Scale 2, the EQ-5D-3L, and the Schwab and England Scale were identified as predictors of costs. CONCLUSION: Costs in this cohort of individuals with late-stage PD were substantially higher compared to previously published data on individuals living in earlier stages of the disease. Resource utilization in the individual sites differed in part considerably among these three parameters mentioned. © 2024 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
dc.description.sponsorshipCare for Late Stage Parkinsonismen_US
dc.language.isoENen_US
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/us/*
dc.subject.enCost-of-illness
dc.subject.enParkinson’s disease
dc.subject.enresource utilization
dc.subject.enlate-stage parkinsonism
dc.title.enCare of Late-Stage Parkinsonism: Resource Utilization of the Disease in Five European Countries
dc.title.alternativeMov Disorden_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1002/mds.29718en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed38425158en_US
bordeaux.journalMovement Disordersen_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.institutionCNRS
bordeaux.teamACTIVE_BPHen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-04501150
hal.version1
hal.date.transferred2024-03-12T13:22:31Z
hal.popularnonen_US
hal.audienceInternationaleen_US
hal.exporttrue
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Movement%20Disorders&rft.date=2024-02-29&rft.eissn=1531-8257%20(Electronic)%200885-3185%20(Linking)&rft.issn=1531-8257%20(Electronic)%200885-3185%20(Linking)&rft.au=KRUSE,%20Christopher&LIPINSKI,%20Anna&VERHEYEN,%20Malte&BALZER-GELDSETZER,%20Monika&WITTENBERG,%20Michael&rft.genre=article


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record